LOGIN  |  REGISTER

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 434.38
13.22 3.14
1.88M
257.53M
US$ 111.870B
US$ 586.69
15.33 2.68
1.29M
108.07M
US$ 63.400B
US$ 283.40
15.85 5.92
1.24M
128.98M
US$ 36.550B
US$ 561.75
29.48 5.54
693,941
59.80M
US$ 33.590B
US$ 92.34
0.26 0.28
1.13M
239.74M
US$ 22.140B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 23.09
0.34 1.49
2.73M
737.45M
US$ 17.030B
US$ 33.12
0.83 2.57
3.18M
444.30M
US$ 14.720B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 303.92
4.24 1.41
484,627
44.64M
US$ 13.570B
US$ 46.26
1.61 3.61
9.96M
285.58M
US$ 13.210B
US$ 19.65
0.57 2.99
1.04M
635.24M
US$ 12.480B
US$ 120.27
1.49 1.25
1.16M
101.25M
US$ 12.180B
US$ 62.76
1.60 2.62
1.61M
192.65M
US$ 12.090B
US$ 67.22
1.61 2.45
1.23M
178.90M
US$ 12.030B
US$ 58.27
-0.43 -0.73
3.23M
190.58M
US$ 11.110B
US$ 157.54
0.34 0.22
334,384
59.81M
US$ 9.420B
US$ 23.65
-0.37 -1.54
14.60M
384.82M
US$ 9.100B
US$ 10.76
0.09 0.84
3.73M
727.95M
US$ 7.830B
US$ 73.36
2.52 3.56
1.12M
104.78M
US$ 7.690B
US$ 48.24
0.38 0.79
2.01M
158.89M
US$ 7.660B
US$ 39.44
-0.04 -0.10
873,262
184.80M
US$ 7.290B
US$ 106.07
-0.52 -0.49
814,013
60.45M
US$ 6.410B
US$ 33.74
0.08 0.24
2.10M
188.99M
US$ 6.380B
US$ 291.82
8.96 3.17
261,813
21.81M
US$ 6.360B
US$ 99.49
1.98 2.03
429,164
63.53M
US$ 6.320B
US$ 48.95
1.04 2.17
3.47M
127.23M
US$ 6.230B
US$ 69.53
2.29 3.41
647,169
81.83M
US$ 5.690B
US$ 33.59
0.19 0.57
1.40M
155.66M
US$ 5.230B
US$ 32.99
0.39 1.20
1.03M
157.90M
US$ 5.210B
US$ 107.22
3.55 3.42
553,707
48.46M
US$ 5.200B
US$ 27.69
-0.11 -0.40
1.91M
183.45M
US$ 5.080B
US$ 31.21
0.59 1.93
722,177
161.80M
US$ 5.050B
US$ 71.00
-0.02 -0.03
396,424
65.62M
US$ 4.660B
US$ 19.20
-2.19 -10.24
2.66M
236.39M
US$ 4.540B
US$ 10.52
0.37 3.65
65,279
411.34M
US$ 4.330B
US$ 23.10
1.02 4.62
777,542
186.89M
US$ 4.320B
US$ 27.32
-0.47 -1.69
1.70M
149.57M
US$ 4.090B
US$ 30.90
1.48 5.03
1.98M
124.64M
US$ 3.850B
US$ 130.33
-1.06 -0.81
578,653
28.76M
US$ 3.750B
US$ 60.18
2.90 5.06
773,538
61.46M
US$ 3.700B
US$ 29.84
-0.16 -0.53
2.27M
118.01M
US$ 3.520B
US$ 28.97
0.57 2.01
956,248
119.31M
US$ 3.460B
US$ 46.08
-0.14 -0.30
4.99M
74.39M
US$ 3.430B
US$ 35.27
-0.47 -1.32
3.87M
95.52M
US$ 3.370B
US$ 75.07
1.61 2.19
528,349
43.12M
US$ 3.240B
US$ 34.84
0.12 0.35
432,569
92.34M
US$ 3.220B
US$ 58.45
-10.88 -15.69
895,113
54.07M
US$ 3.160B
US$ 10.46
-0.04 -0.38
176,420
301.94M
US$ 3.160B
US$ 28.75
0.61 2.17
765,067
108.94M
US$ 3.130B
US$ 36.31
0.71 1.99
1.38M
85.35M
US$ 3.100B
US$ 17.60
0.03 0.17
1.93M
166.39M
US$ 2.930B
US$ 31.21
-0.08 -0.26
750,807
92.74M
US$ 2.890B
US$ 30.83
0.29 0.95
878,026
93.62M
US$ 2.890B
US$ 23.78
0.38 1.62
791,709
119.27M
US$ 2.840B
US$ 39.96
2.08 5.49
1.39M
69.80M
US$ 2.790B
US$ 39.84
-0.56 -1.39
737,735
68.46M
US$ 2.730B
US$ 44.41
0.64 1.46
508,355
59.60M
US$ 2.650B
US$ 37.66
0.67 1.81
345,008
63.06M
US$ 2.370B
US$ 13.92
0.14 1.02
648,551
169.28M
US$ 2.360B
US$ 29.57
-0.17 -0.57
1.03M
76.24M
US$ 2.250B
US$ 28.49
0.00 0.00
1.04M
77.50M
US$ 2.210B
US$ 45.28
0.89 2.00
222,470
48.00M
US$ 2.170B
US$ 10.21
0.36 3.65
6.45M
207.13M
US$ 2.110B
US$ 67.30
5.70 9.25
52,368
30.88M
US$ 2.080B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 41.49
-0.81 -1.91
439,024
49.36M
US$ 2.050B
US$ 16.36
-0.34 -2.04
2.41M
124.39M
US$ 2.040B
US$ 14.16
0.20 1.43
864,280
143.92M
US$ 2.040B
US$ 18.70
-0.05 -0.27
657,724
107.05M
US$ 2.000B
US$ 103.47
-1.62 -1.54
82,307
18.90M
US$ 1.960B
US$ 34.23
0.84 2.52
520,793
57.03M
US$ 1.950B
US$ 2.67
0.18 7.23
9.30M
730.16M
US$ 1.950B
US$ 30.02
0.27 0.91
435,814
64.77M
US$ 1.940B
US$ 25.35
1.18 4.88
554,101
76.13M
US$ 1.930B
US$ 15.34
0.43 2.88
2.03M
124.43M
US$ 1.910B
US$ 21.15
0.06 0.28
837,706
87.03M
US$ 1.840B
US$ 5.95
0.07 1.19
3.22M
298.81M
US$ 1.780B
US$ 26.86
0.36 1.36
554,472
65.90M
US$ 1.770B
US$ 40.64
0.79 1.98
426,132
43.42M
US$ 1.760B
US$ 12.59
0.32 2.61
496,164
131.84M
US$ 1.660B
US$ 43.50
0.60 1.40
741,046
38.23M
US$ 1.660B
US$ 19.30
0.65 3.49
1.77M
84.64M
US$ 1.630B
US$ 28.26
0.23 0.82
422,348
57.03M
US$ 1.610B
US$ 13.63
0.03 0.22
1.37M
117.04M
US$ 1.600B
US$ 15.87
-3.79 -19.28
7.56M
101.12M
US$ 1.600B
US$ 17.31
0.21 1.23
693,095
86.43M
US$ 1.500B
US$ 17.07
0.07 0.41
647,045
88.07M
US$ 1.500B
US$ 29.06
1.37 4.95
545,262
50.03M
US$ 1.450B
US$ 17.25
0.01 0.06
1.18M
82.81M
US$ 1.430B
US$ 24.43
0.61 2.56
394,173
57.26M
US$ 1.400B
US$ 47.09
1.36 2.97
298,385
29.76M
US$ 1.400B
US$ 11.95
0.41 3.55
258,086
115.65M
US$ 1.380B
US$ 14.45
-0.10 -0.69
1.10M
94.69M
US$ 1.370B
US$ 23.27
0.65 2.87
1.73M
58.63M
US$ 1.360B
US$ 21.33
0.14 0.66
552,673
63.32M
US$ 1.350B
US$ 20.10
1.16 6.12
588,064
66.34M
US$ 1.330B
US$ 8.91
1.90 27.10
887,104
147.58M
US$ 1.310B
US$ 7.41
0.64 9.45
143,635
170.74M
US$ 1.270B
US$ 4.56
-0.01 -0.22
1.32M
275.78M
US$ 1.260B
US$ 9.51
0.11 1.17
1.32M
131.46M
US$ 1.250B
US$ 11.74
0.04 0.34
1.07M
101.77M
US$ 1.190B
US$ 12.20
0.10 0.83
1.77M
97.19M
US$ 1.190B
US$ 8.15
0.30 3.82
1.63M
143.18M
US$ 1.170B
US$ 18.33
0.32 1.78
632,255
62.60M
US$ 1.150B
US$ 7.17
0.24 3.46
1.47M
157.22M
US$ 1.130B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 6.29
0.33 5.54
9.94M
160.18M
US$ 1.010B
US$ 12.62
0.24 1.94
460,913
79.21M
US$ 999.630M
US$ 6.30
-0.05 -0.79
1.35M
152.52M
US$ 960.880M
US$ 10.94
0.55 5.29
49,728
85.82M
US$ 938.870M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 7.64
-0.56 -6.83
1.63M
117.58M
US$ 898.310M
US$ 17.82
-2.07 -10.41
800,519
48.86M
US$ 870.690M
US$ 14.54
-0.26 -1.76
443,404
59.80M
US$ 869.490M
US$ 15.91
-0.16 -1.00
22,751
54.23M
US$ 862.800M
US$ 8.07
0.19 2.41
1.89M
101.85M
US$ 821.930M
US$ 3.38
0.10 3.05
4.08M
236.85M
US$ 800.550M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 11.53
0.28 2.49
330,034
68.88M
US$ 794.190M
US$ 14.47
0.77 5.62
296,248
54.42M
US$ 787.460M
US$ 8.57
0.03 0.35
774,315
91.51M
US$ 784.240M
US$ 18.45
1.17 6.77
13,165
41.94M
US$ 773.790M
US$ 3.43
0.06 1.63
436,338
224.34M
US$ 768.360M
US$ 15.36
0.25 1.65
1.32M
49.77M
US$ 764.470M
US$ 8.95
-0.33 -3.56
3.49M
85.36M
US$ 763.970M
US$ 27.34
-0.29 -1.05
155,025
27.50M
US$ 751.850M
US$ 2.24
0.07 3.23
2.27M
335.57M
US$ 751.680M
US$ 1.21
0.02 1.68
6.22M
604.50M
US$ 731.440M
US$ 6.85
0.79 13.04
6.41M
106.34M
US$ 728.430M
US$ 4.79
0.15 3.23
1.72M
149.08M
US$ 714.090M
US$ 8.37
0.20 2.45
682,841
84.82M
US$ 709.940M
US$ 11.69
0.07 0.60
879,856
60.68M
US$ 709.350M
US$ 13.25
0.60 4.74
1.12M
53.44M
US$ 708.080M
US$ 37.20
0.10 0.27
320,883
18.64M
US$ 693.410M
US$ 5.44
0.59 12.16
110,336
126.19M
US$ 686.470M
US$ 9.46
-0.12 -1.25
435,581
70.84M
US$ 670.150M
US$ 19.24
0.49 2.61
165,763
33.70M
US$ 648.390M
US$ 4.55
0.05 1.11
1.21M
137.72M
US$ 626.630M
US$ 20.40
0.95 4.88
361,076
30.43M
US$ 620.770M
US$ 6.15
-0.04 -0.65
1.21M
100.85M
US$ 620.230M
US$ 9.14
-0.02 -0.22
2,354
67.84M
US$ 619.720M
US$ 2.05
-0.98 -32.34
3.06M
295.37M
US$ 605.510M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 3.12
-0.09 -2.80
947,202
189.49M
US$ 591.210M
US$ 11.66
0.32 2.82
350,121
49.42M
US$ 576.240M
US$ 8.20
0.06 0.74
995,140
69.98M
US$ 573.840M
US$ 4.69
0.13 2.85
786,620
121.55M
US$ 570.070M
US$ 14.03
0.44 3.24
1.04M
40.51M
US$ 568.360M
US$ 10.70
0.72 7.21
72,966
52.03M
US$ 556.720M
US$ 7.23
0.22 3.14
689,416
76.96M
US$ 556.420M
US$ 18.75
-0.15 -0.79
245,675
29.60M
US$ 555.000M
US$ 2.54
0.09 3.67
3.58M
218.18M
US$ 554.180M
US$ 6.19
0.00 0.00
1.31M
89.37M
US$ 553.200M
US$ 1.76
0.06 3.53
14.28M
304.78M
US$ 536.410M
US$ 3.11
0.12 4.01
480,724
171.62M
US$ 533.740M
US$ 4.77
-0.11 -2.25
699,807
110.46M
US$ 526.890M
US$ 3.41
0.00 0.00
0
153.89M
US$ 524.760M
US$ 2.56
0.19 8.02
6.64M
204.94M
US$ 524.650M
US$ 3.02
-0.22 -6.79
196,733
170.55M
US$ 515.060M
US$ 7.85
0.01 0.13
769,622
65.50M
US$ 514.170M
US$ 19.70
2.58 15.07
655,643
26.05M
US$ 513.180M
US$ 9.63
0.64 7.12
586,215
52.97M
US$ 510.100M
US$ 6.16
-0.25 -3.90
3,263
81.20M
US$ 500.190M
US$ 8.00
0.03 0.38
1.20M
62.42M
US$ 499.360M
US$ 9.86
0.19 1.96
129,902
50.60M
US$ 498.920M
US$ 6.60
0.06 0.92
632,274
73.33M
US$ 483.980M
US$ 8.78
0.22 2.57
237,907
53.60M
US$ 470.610M
US$ 2.79
0.02 0.72
768,943
167.38M
US$ 466.990M
US$ 5.95
0.22 3.84
1.12M
77.76M
US$ 462.670M
US$ 8.43
0.29 3.56
721,929
53.38M
US$ 449.990M
US$ 9.14
0.73 8.68
371,418
49.17M
US$ 449.410M
US$ 9.86
-0.30 -2.95
3.32M
44.40M
US$ 437.780M
US$ 9.56
1.89 24.64
4.78M
45.47M
US$ 434.690M
US$ 6.26
0.19 3.13
1.99M
68.71M
US$ 430.120M
US$ 8.64
0.31 3.72
880,109
49.55M
US$ 428.110M
US$ 4.75
-0.03 -0.63
5.56M
89.70M
US$ 426.080M
US$ 5.92
-0.26 -4.21
389,406
71.40M
US$ 422.690M
US$ 7.24
0.11 1.54
284,707
58.23M
US$ 421.590M
US$ 9.85
-0.02 -0.20
839,348
42.20M
US$ 415.670M
US$ 17.35
0.63 3.77
573
23.94M
US$ 415.310M
US$ 4.89
0.07 1.45
419,685
84.69M
US$ 414.130M
US$ 3.09
0.002 0.06
13,249
133.17M
US$ 411.760M
US$ 5.78
0.08 1.40
1.70M
71.12M
US$ 411.070M
US$ 6.61
0.23 3.61
657,072
61.17M
US$ 404.330M
US$ 15.52
0.02 0.13
107,683
25.64M
US$ 397.930M
US$ 5.04
0.40 8.62
509,186
78.15M
US$ 393.880M
US$ 10.52
-0.34 -3.13
169,685
37.13M
US$ 390.610M
US$ 5.72
0.24 4.38
588,822
68.25M
US$ 390.390M
US$ 4.52
0.17 3.91
439,311
85.69M
US$ 387.320M
US$ 8.12
0.11 1.37
279,926
47.55M
US$ 386.110M
US$ 1.31
0.03 2.34
3.11M
292.87M
US$ 383.660M
US$ 1.71
-0.07 -3.93
2.80M
223.27M
US$ 381.790M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 5.99
-0.17 -2.76
34,123
63.35M
US$ 379.470M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 0.29
0.0028 0.99
1.05M
1.32B
US$ 376.200M
US$ 4.32
0.01 0.23
2.48M
84.66M
US$ 365.730M
US$ 8.20
-0.61 -6.92
310,494
44.54M
US$ 365.230M
US$ 6.72
-0.17 -2.47
1.12M
53.81M
US$ 361.330M
US$ 1.27
0.00 0.00
1.79M
282.73M
US$ 359.070M
US$ 9.76
0.12 1.25
100,346
36.58M
US$ 356.840M
US$ 6.60
0.97 17.23
1.17M
53.94M
US$ 356.000M
US$ 10.65
0.48 4.72
142,257
33.42M
US$ 355.920M
US$ 7.90
0.77 10.80
1.67M
44.51M
US$ 351.630M
US$ 4.69
0.19 4.22
419,791
74.24M
US$ 348.190M
US$ 19.74
1.46 7.99
240,685
17.61M
US$ 347.620M
US$ 7.67
-0.16 -2.04
588,979
45.20M
US$ 346.680M
US$ 1.29
0.07 5.74
1.54M
266.12M
US$ 343.290M
US$ 2.96
0.19 6.86
2.72M
114.86M
US$ 339.990M
US$ 2.18
-0.13 -5.63
913,300
155.15M
US$ 338.230M
US$ 4.74
-0.12 -2.47
572,403
70.57M
US$ 334.500M
US$ 11.64
0.80 7.38
375,878
27.09M
US$ 315.330M
US$ 13.50
-0.08 -0.59
29,428
23.22M
US$ 313.470M
US$ 26.55
-0.19 -0.71
14,562
11.78M
US$ 312.760M
US$ 8.12
0.15 1.88
97,254
37.42M
US$ 303.850M
US$ 2.01
0.18 9.84
614,364
145.46M
US$ 292.370M
US$ 7.97
0.37 4.87
5.56M
36.53M
US$ 291.140M
US$ 5.35
0.84 18.63
1.11M
54.41M
US$ 291.090M
US$ 19.37
4.15 27.27
509,050
14.85M
US$ 287.640M
US$ 7.18
-0.32 -4.27
13,858
39.63M
US$ 284.540M
US$ 1.87
0.15 8.72
1.88M
152.10M
US$ 284.430M
US$ 6.50
-0.05 -0.76
40,645
43.64M
US$ 283.660M
C$ 4.00
0.40 11.11
276,197
70.31M
C$ 281.240M
US$ 1.96
-0.02 -1.01
2.88M
141.84M
US$ 278.010M
US$ 1.63
0.20 13.99
2.44M
167.80M
US$ 273.510M
US$ 10.43
0.45 4.51
60,192
25.73M
US$ 268.360M
US$ 5.18
0.28 5.71
482,566
49.95M
US$ 258.740M
US$ 4.99
0.00 0.00
0
51.59M
US$ 257.430M
US$ 5.79
0.07 1.22
1.89M
43.59M
US$ 252.390M
US$ 3.00
-0.03 -0.99
1.37M
83.94M
US$ 251.820M
US$ 3.60
0.35 10.77
1.23M
68.38M
US$ 246.170M
US$ 1.89
0.02 1.07
4.28M
128.67M
US$ 243.190M
US$ 39.55
2.44 6.58
16,422
6.10M
US$ 241.250M
US$ 4.31
0.20 4.87
75,006
55.59M
US$ 239.590M
US$ 1.29
0.04 3.20
913,239
185.72M
US$ 239.580M
US$ 1.05
0.04 3.96
1.72M
226.60M
US$ 237.930M
US$ 3.87
0.17 4.59
369,046
61.44M
US$ 237.770M
US$ 11.26
-0.22 -1.92
101,085
20.52M
US$ 231.060M
US$ 21.04
1.74 9.02
271,613
10.95M
US$ 230.390M
US$ 3.58
-0.04 -1.10
663,162
64.26M
US$ 230.050M
US$ 3.93
0.01 0.26
673,745
58.31M
US$ 229.160M
US$ 3.95
0.02 0.51
1.53M
57.95M
US$ 228.900M
US$ 1.09
0.14 14.40
4.38M
209.67M
US$ 228.540M
US$ 5.11
-0.23 -4.31
576,099
44.48M
US$ 227.290M
US$ 32.36
0.66 2.08
15,733
6.99M
US$ 226.200M
US$ 2.59
0.04 1.57
456,810
84.46M
US$ 218.750M
US$ 2.17
0.13 6.11
2.22M
100.33M
US$ 217.720M
US$ 2.38
0.16 7.21
3.42M
91.18M
US$ 217.010M
US$ 19.99
0.56 2.88
63,987
10.79M
US$ 215.690M
US$ 7.67
-0.14 -1.84
2,786
27.86M
US$ 213.690M
US$ 2.96
0.13 4.56
22,251
70.10M
US$ 207.430M
US$ 3.56
0.07 2.01
713,381
57.94M
US$ 206.270M
US$ 2.51
0.04 1.62
1.60M
81.38M
US$ 204.260M
US$ 0.70
0.0054 0.78
5.23M
291.32M
US$ 203.920M
US$ 4.15
0.00 0.00
856,694
48.13M
US$ 199.740M
US$ 3.98
-0.07 -1.73
7,256
49.91M
US$ 198.640M
US$ 0.53
-0.0019 -0.36
4.33M
361.49M
US$ 191.590M
US$ 3.36
0.14 4.35
45,356
56.62M
US$ 190.240M
C$ 5.28
-0.01 -0.19
19,830
35.62M
C$ 188.070M
US$ 1.55
0.03 1.97
1.01M
121.01M
US$ 187.570M
US$ 9.57
2.82 41.78
11,170
19.53M
US$ 186.900M
US$ 3.99
0.15 3.91
686,909
46.03M
US$ 183.660M
US$ 1.72
-0.04 -2.27
1.30M
106.59M
US$ 183.330M
US$ 2.75
0.08 3.00
676,185
66.52M
US$ 182.930M
US$ 6.55
0.22 3.48
68,326
27.43M
US$ 179.670M
US$ 12.24
0.92 8.13
92,516
14.65M
US$ 179.320M
US$ 9.28
0.04 0.43
121,157
19.32M
US$ 179.290M
US$ 3.28
0.09 2.82
271,128
54.63M
US$ 179.190M
US$ 3.37
-0.13 -3.73
15,750
52.36M
US$ 176.450M
US$ 3.33
-0.61 -15.48
1.15M
52.62M
US$ 175.220M
US$ 2.11
0.03 1.44
10,375
82.78M
US$ 174.670M
US$ 12.02
1.18 10.89
71,876
14.48M
US$ 174.050M
US$ 4.07
0.07 1.75
115,951
42.76M
US$ 174.030M
US$ 3.67
-0.21 -5.29
2,654
47.40M
US$ 173.960M
US$ 3.86
0.22 6.04
140,304
44.79M
US$ 172.890M
US$ 2.89
0.06 2.12
177,219
59.74M
US$ 172.650M
US$ 1.63
0.08 5.16
278,569
105.91M
US$ 172.630M
US$ 1.28
0.07 5.79
847,642
131.16M
US$ 167.880M
US$ 1.69
0.48 39.67
522,451
96.69M
US$ 163.410M
US$ 1.52
0.24 18.29
794,985
107.42M
US$ 163.280M
US$ 4.00
-0.53 -11.70
122,707
40.44M
US$ 161.760M
US$ 7.29
-0.14 -1.88
196,320
22.17M
US$ 161.620M
US$ 3.28
0.38 13.10
867,887
49.09M
US$ 161.020M
US$ 2.00
-0.38 -15.97
9.12M
78.26M
US$ 156.520M
US$ 1.57
-0.53 -25.24
59,876
98.94M
US$ 155.340M
US$ 0.78
0.05 6.44
9.17M
197.04M
US$ 153.100M
US$ 1.49
0.11 7.97
24,674
100.09M
US$ 149.130M
US$ 3.20
0.07 2.24
321,049
46.23M
US$ 147.940M
US$ 1.39
-0.06 -4.14
258,699
103.82M
US$ 144.310M
US$ 2.88
0.64 28.57
1.69M
50.04M
US$ 144.120M
US$ 3.85
-0.06 -1.53
6,599
36.86M
US$ 141.910M
US$ 2.03
-0.09 -4.25
89,544
69.36M
US$ 140.800M
US$ 3.82
0.06 1.60
151,166
35.85M
US$ 136.950M
US$ 14.48
0.37 2.62
70,947
9.37M
US$ 135.680M
US$ 1.22
-0.38 -23.75
533,485
107.02M
US$ 130.560M
US$ 2.92
-0.08 -2.67
181,090
44.20M
US$ 129.060M
US$ 2.16
-0.01 -0.46
512,985
59.55M
US$ 128.630M
US$ 6.40
0.02 0.31
208,411
19.99M
US$ 127.940M
US$ 9.69
0.27 2.87
18,873
13.14M
US$ 127.330M
US$ 1.13
-0.05 -4.24
100,115
111.42M
US$ 125.900M
US$ 0.68
-0.04 -4.90
1.91M
184.46M
US$ 125.430M
US$ 0.99
-0.04 -4.27
1.07M
125.80M
US$ 124.040M
US$ 1.67
0.00 0.00
646,401
73.63M
US$ 122.960M
US$ 1.37
0.06 4.58
265,268
89.54M
US$ 122.670M
US$ 1.72
-0.15 -8.02
756,877
70.57M
US$ 121.380M
US$ 1.87
0.08 4.47
991,138
63.81M
US$ 119.320M
US$ 0.40
0.01 3.08
327,826
292.16M
US$ 117.450M
US$ 1.40
0.02 1.09
971,076
82.55M
US$ 115.160M
US$ 1.01
0.05 5.21
928,709
113.89M
US$ 115.030M
US$ 2.08
-0.03 -1.42
179,583
54.92M
US$ 114.230M
US$ 5.37
0.19 3.67
81,540
21.19M
US$ 113.790M
US$ 1.60
0.09 5.96
2.47M
70.38M
US$ 112.610M
C$ 1.69
-0.01 -0.59
200
64.94M
C$ 109.750M
US$ 2.89
0.07 2.48
154,598
37.82M
US$ 109.300M
US$ 1.93
0.04 2.12
1.41M
56.59M
US$ 109.220M
US$ 0.85
0.08 10.23
552,921
127.97M
US$ 108.770M
US$ 0.86
-0.02 -2.22
93,545
125.56M
US$ 108.230M
US$ 1.11
0.04 3.27
1.33M
97.93M
US$ 108.210M
US$ 0.67
0.05 8.28
989,459
161.56M
US$ 107.600M
US$ 3.11
-0.02 -0.64
291,327
34.32M
US$ 106.740M
US$ 6.81
1.44 26.82
100,075
15.53M
US$ 105.760M
US$ 1.78
-0.06 -3.26
219,574
58.88M
US$ 104.810M
US$ 0.47
0.01 2.62
667,737
220.42M
US$ 103.600M
US$ 2.59
0.04 1.57
995,641
39.95M
US$ 103.470M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 3.31
0.21 6.77
281,907
30.67M
US$ 101.520M
US$ 2.05
0.17 9.04
1.56M
48.11M
US$ 98.630M
US$ 5.87
0.18 3.16
37,421
16.71M
US$ 98.090M
US$ 1.96
0.05 2.62
667,842
49.81M
US$ 97.630M
US$ 14.81
1.52 11.44
65,351
6.53M
US$ 96.710M
US$ 1.54
-0.01 -0.65
239,543
62.76M
US$ 96.650M
US$ 0.42
0.02 6.00
1.45M
227.48M
US$ 96.450M
US$ 2.32
-0.05 -2.11
39,254
40.88M
US$ 94.840M
US$ 2.18
0.03 1.40
379,386
43.17M
US$ 94.110M
US$ 0.45
0.01 2.74
4.72M
208.65M
US$ 93.890M
US$ 2.73
-0.08 -2.85
125,725
34.39M
US$ 93.880M
US$ 1.42
0.07 5.19
3.63M
64.24M
US$ 91.220M
US$ 2.98
0.10 3.47
27,817
30.48M
US$ 90.830M
US$ 2.80
0.25 9.80
61,223
32.20M
US$ 90.160M
US$ 1.26
0.07 5.88
606,982
71.27M
US$ 89.800M
US$ 1.00
0.02 1.92
561,797
90.08M
US$ 89.720M
US$ 2.70
0.01 0.37
802,645
33.08M
US$ 89.320M
US$ 2.20
-0.01 -0.45
65,025
40.31M
US$ 88.680M
US$ 0.77
-0.02 -2.80
2.38M
115.21M
US$ 88.480M
US$ 7.21
0.17 2.41
60,090
12.18M
US$ 87.820M
US$ 6.28
-0.19 -2.94
6,228
13.70M
US$ 86.040M
US$ 1.75
0.45 34.69
6.99M
48.88M
US$ 85.590M
US$ 1.21
0.03 2.54
424,594
70.71M
US$ 85.560M
US$ 0.70
-0.13 -15.78
2.90M
119.62M
US$ 84.210M
C$ 1.07
0.02 1.90
10,983
78.16M
C$ 83.630M
US$ 2.42
0.02 0.83
104,106
34.54M
US$ 83.590M
US$ 1.37
0.01 0.74
421,176
60.85M
US$ 83.360M
US$ 1.32
0.02 1.54
106,798
62.76M
US$ 82.840M
US$ 1.66
0.13 8.14
163,195
48.10M
US$ 79.850M
US$ 3.38
-0.09 -2.59
688,375
23.61M
US$ 79.800M
US$ 12.50
0.39 3.22
16,072
6.36M
US$ 79.500M
US$ 1.77
0.24 15.69
15,237
44.27M
US$ 78.360M
US$ 1.20
0.03 2.56
205,888
65.29M
US$ 78.350M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 4.21
0.04 0.96
1,037
18.29M
US$ 77.000M
US$ 0.84
0.02 2.58
705,406
90.55M
US$ 76.060M
US$ 1.71
-0.01 -0.58
40,246
44.39M
US$ 75.910M
US$ 3.94
0.10 2.60
85,420
19.05M
US$ 75.060M
US$ 0.90
0.17 22.78
1.76M
82.46M
US$ 74.210M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 2.01
0.03 1.26
54,223
36.83M
US$ 73.840M
US$ 4.87
0.02 0.41
90,942
15.00M
US$ 73.050M
C$ 0.64
0.00 0.00
74,510
113.60M
C$ 72.700M
US$ 1.46
0.09 6.57
191,611
49.63M
US$ 72.460M
US$ 1.26
0.11 9.57
538,515
57.49M
US$ 72.440M
US$ 0.89
0.0027 0.31
69,187
81.50M
US$ 72.130M
US$ 1.53
0.00 0.00
0
46.60M
US$ 71.300M
US$ 8.64
0.32 3.85
182,483
8.25M
US$ 71.280M
C$ 0.22
0.00 0.00
40,000
328.48M
C$ 70.620M
US$ 1.95
0.07 3.72
412,602
36.10M
US$ 70.400M
US$ 2.36
-0.30 -11.28
348,930
29.75M
US$ 70.210M
C$ 2.55
0.02 0.79
1,700
27.40M
C$ 69.870M
US$ 1.39
0.02 1.46
16,748
49.05M
US$ 68.180M
US$ 0.27
0.03 11.25
499,751
255.88M
US$ 67.810M
US$ 1.68
-0.0045 -0.27
6,610
40.30M
US$ 67.700M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 1.02
0.04 4.08
70,118
65.88M
US$ 67.200M
C$ 0.89
0.00 0.00
0
74.57M
C$ 66.370M
US$ 1.11
0.04 3.74
369,109
59.47M
US$ 66.010M
US$ 2.43
0.23 10.45
170,221
26.97M
US$ 65.540M
US$ 0.86
0.01 1.17
377,591
75.84M
US$ 65.530M
US$ 5.50
-0.67 -10.86
112,001
11.80M
US$ 64.900M
US$ 1.31
0.03 2.34
302,233
49.09M
US$ 64.310M
US$ 2.30
0.04 1.77
129,853
27.84M
US$ 64.030M
US$ 7.69
0.04 0.52
196,353
8.19M
US$ 62.980M
US$ 5.60
-0.04 -0.71
9,128
11.11M
US$ 62.220M
US$ 1.15
-0.02 -1.71
764,383
53.33M
US$ 61.330M
US$ 1.01
-0.88 -46.56
92,309
60.08M
US$ 60.680M
US$ 17.00
0.00 0.00
0
3.55M
US$ 60.350M
US$ 0.39
-0.01 -3.00
571,531
153.83M
US$ 59.690M
US$ 1.95
0.05 2.63
134,772
30.34M
US$ 59.160M
US$ 22.41
1.10 5.16
5,566
2.61M
US$ 58.490M
US$ 1.56
0.06 4.00
393,376
37.42M
US$ 58.380M
US$ 0.64
0.11 19.75
512,552
90.56M
US$ 58.050M
US$ 1.85
0.00 0.00
0
31.24M
US$ 57.790M
US$ 5.30
-0.11 -2.03
7,098
10.79M
US$ 57.190M
US$ 0.55
-0.0073 -1.31
1.20M
103.80M
US$ 57.190M
US$ 0.49
0.0058 1.20
941,399
116.36M
US$ 57.130M
US$ 1.33
0.03 1.92
100,581
42.51M
US$ 56.540M
US$ 0.75
-0.04 -5.06
66,349
75.00M
US$ 56.250M
US$ 1.10
0.02 1.85
38,097
48.26M
US$ 53.090M
US$ 5.64
0.03 0.53
3,075
9.39M
US$ 52.960M
C$ 0.08
-0.005 -6.25
181,000
701.73M
C$ 52.630M
US$ 0.64
-0.0069 -1.07
410,615
82.40M
US$ 52.570M
US$ 1.43
-0.03 -2.05
519,051
36.24M
US$ 51.820M
US$ 2.12
0.31 17.13
244,421
24.29M
US$ 51.490M
US$ 2.36
0.11 4.89
247,126
21.67M
US$ 51.140M
US$ 0.32
-0.01 -3.03
12.90M
158.72M
US$ 50.790M
US$ 10.10
0.00 0.00
0
5.02M
US$ 50.700M
US$ 1.40
0.02 1.45
2,917
36.18M
US$ 50.650M
US$ 1.35
0.04 3.05
215,135
37.41M
US$ 50.500M
US$ 7.83
0.23 3.03
30,082
6.39M
US$ 50.030M
US$ 1.11
0.12 12.12
1.32M
44.56M
US$ 49.460M
US$ 1.78
0.12 7.23
215,348
27.60M
US$ 49.130M
US$ 4.97
-0.01 -0.20
711,882
9.72M
US$ 48.310M
C$ 0.68
-0.01 -1.45
11,500
70.89M
C$ 48.210M
US$ 1.81
-0.05 -2.69
372,847
26.53M
US$ 48.020M
US$ 1.53
0.07 4.79
182,224
31.20M
US$ 47.740M
US$ 0.99
0.08 9.38
23,095
47.74M
US$ 47.260M
US$ 5.30
0.39 7.94
46,607
8.91M
US$ 47.220M
C$ 0.96
0.00 0.00
0
49.02M
C$ 47.060M
US$ 1.39
0.05 3.73
8,806
33.84M
US$ 47.040M
US$ 2.79
0.19 7.31
33,283
16.84M
US$ 46.980M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 1.43
0.05 3.62
163,303
32.60M
US$ 46.620M
US$ 1.77
0.01 0.57
3.51M
26.16M
US$ 46.300M
US$ 0.54
0.05 10.41
390,301
85.03M
US$ 45.920M
C$ 0.34
-0.02 -5.56
77,575
134.53M
C$ 45.740M
US$ 1.99
-0.03 -1.49
62,606
22.48M
US$ 44.740M
C$ 0.92
-0.03 -3.16
24,500
47.65M
C$ 43.840M
US$ 7.61
1.00 15.13
190,538
5.76M
US$ 43.830M
US$ 0.84
-0.0078 -0.92
105,324
51.75M
US$ 43.370M
US$ 2.53
-0.03 -1.17
130,635
17.06M
US$ 43.160M
US$ 0.71
-0.02 -2.76
2.23M
60.34M
US$ 42.540M
US$ 2.03
-0.88 -30.24
757,022
20.80M
US$ 42.220M
US$ 1.68
-0.07 -4.01
319,741
24.91M
US$ 41.720M
US$ 3.86
-0.20 -4.93
46,170
10.78M
US$ 41.610M
US$ 1.01
0.03 3.06
17,366
41.08M
US$ 41.490M
US$ 2.04
0.18 9.68
127,247
20.16M
US$ 41.130M
US$ 3.86
0.26 7.22
31,346
10.50M
US$ 40.530M
US$ 0.73
-0.04 -5.58
151,942
55.25M
US$ 40.170M
US$ 1.29
0.03 1.98
99,940
31.05M
US$ 39.900M
US$ 0.49
0.02 4.14
191,434
79.97M
US$ 39.430M
US$ 1.15
0.01 0.88
171,271
34.08M
US$ 39.190M
US$ 0.84
0.05 6.20
294,666
46.58M
US$ 39.080M
US$ 0.92
0.02 2.34
122,291
42.18M
US$ 38.970M
US$ 0.31
-0.07 -17.37
4.10M
123.53M
US$ 38.790M
US$ 0.50
-0.02 -3.47
462,438
77.07M
US$ 38.530M
C$ 0.34
0.00 0.00
107,945
111.72M
C$ 37.980M
US$ 1.69
0.20 13.42
90,571
22.30M
US$ 37.690M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 0.84
-0.0014 -0.17
531,321
44.00M
US$ 36.960M
US$ 0.80
-0.05 -5.88
1.00M
45.72M
US$ 36.580M
US$ 1.02
0.19 22.67
744,512
35.20M
US$ 35.900M
US$ 0.66
0.0059 0.91
119,685
54.52M
US$ 35.770M
US$ 1.66
-0.14 -7.78
310,836
21.24M
US$ 35.260M
US$ 0.87
-0.02 -2.25
65,609
40.23M
US$ 35.000M
US$ 1.32
-0.03 -2.22
3,161
26.47M
US$ 34.940M
US$ 4.55
-0.40 -8.08
184,971
7.67M
US$ 34.900M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 1.10
-4.26 -79.48
529,083
31.14M
US$ 34.250M
US$ 0.94
-0.05 -5.05
95,061
36.18M
US$ 34.010M
US$ 0.43
0.04 9.82
2.96M
79.22M
US$ 33.750M
C$ 0.73
0.00 0.00
37,500
46.03M
C$ 33.600M
US$ 1.26
-0.01 -0.79
6,513
26.30M
US$ 33.140M
US$ 3.79
-0.31 -7.56
34,488
8.74M
US$ 33.120M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 10.51
-0.16 -1.50
12,003
3.04M
US$ 31.950M
US$ 0.30
0.0021 0.70
1.15M
100.77M
US$ 30.430M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 2.42
0.00 0.00
0
12.54M
US$ 30.350M
US$ 4.12
-0.01 -0.24
18,017
7.30M
US$ 30.040M
US$ 1.00
-0.05 -4.33
54,522
29.59M
US$ 29.440M
US$ 0.33
0.00 0.00
0
89.34M
US$ 29.390M
US$ 1.26
0.04 3.46
173,924
23.23M
US$ 29.270M
US$ 2.39
0.12 5.29
559,732
12.09M
US$ 28.900M
US$ 1.21
0.63 108.19
444,300
23.69M
US$ 28.660M
US$ 0.81
0.06 7.84
499,948
34.96M
US$ 28.280M
US$ 1.81
-0.10 -5.24
17,116
15.49M
US$ 28.040M
US$ 5.04
0.19 3.89
28,508
5.56M
US$ 28.020M
US$ 2.71
0.01 0.37
6,250
10.14M
US$ 27.510M
US$ 15.27
1.13 7.99
31,475
1.78M
US$ 27.180M
US$ 2.33
-0.02 -0.85
1,458
11.54M
US$ 26.890M
US$ 1.12
0.07 6.67
235,055
24.00M
US$ 26.880M
US$ 1.94
0.03 1.41
38,489
13.48M
US$ 26.150M
US$ 2.06
0.23 12.57
2.47M
12.65M
US$ 26.060M
US$ 0.93
-0.01 -1.23
532,745
27.52M
US$ 25.540M
US$ 3.03
-0.10 -3.19
2,808
8.36M
US$ 25.330M
US$ 0.38
-0.0068 -1.78
203,957
66.79M
US$ 25.110M
US$ 2.88
-0.01 -0.35
13,044
8.70M
US$ 25.060M
C$ 0.20
0.005 2.63
7,500
127.82M
C$ 24.920M
US$ 0.43
0.02 4.76
419,699
58.02M
US$ 24.890M
US$ 1.29
0.08 6.61
191,828
18.86M
US$ 24.330M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 6.52
0.40 6.54
16,445
3.65M
US$ 23.800M
C$ 0.16
0.005 3.23
16,500
148.22M
C$ 23.720M
US$ 1.69
0.00 0.00
177,941
13.80M
US$ 23.320M
US$ 0.44
-0.02 -5.09
425,651
52.74M
US$ 22.990M
US$ 1.61
-0.70 -30.30
45,968
14.23M
US$ 22.910M
US$ 1.03
0.00 0.00
12,892
21.99M
US$ 22.650M
US$ 0.29
0.0014 0.48
98,053
77.45M
US$ 22.620M
US$ 6.85
0.35 5.38
12,995
3.25M
US$ 22.260M
US$ 1.23
0.04 3.36
66,737
18.06M
US$ 22.210M
US$ 3.06
-0.22 -6.71
198,829
7.14M
US$ 21.850M
C$ 0.25
0.02 6.52
47,956
88.52M
C$ 21.690M
US$ 0.31
0.01 3.42
504,356
71.01M
US$ 21.660M
US$ 0.17
0.00 0.00
1.69M
124.54M
US$ 21.300M
C$ 0.15
0.00 0.00
0
140.03M
C$ 21.000M
US$ 0.05
-0.0077 -13.12
9,225
407.29M
US$ 20.770M
US$ 2.58
-0.08 -3.01
32,386
7.98M
US$ 20.590M
US$ 1.08
-0.07 -6.17
27,326
19.08M
US$ 20.550M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 2.40
0.22 10.09
15,996
8.39M
US$ 20.140M
US$ 5.80
0.24 4.32
132,753
3.46M
US$ 20.070M
US$ 3.73
0.57 18.04
83,526
5.35M
US$ 19.960M
US$ 5.70
0.02 0.35
11,636
3.41M
US$ 19.440M
US$ 2.84
-0.06 -2.07
64,807
6.80M
US$ 19.310M
US$ 0.57
0.01 2.55
353,523
33.31M
US$ 19.020M
US$ 1.31
0.05 3.97
48,112
14.35M
US$ 18.800M
US$ 1.64
0.005 0.31
4,461
11.45M
US$ 18.780M
US$ 1.40
0.05 3.70
90,205
13.35M
US$ 18.690M
US$ 1.04
-0.06 -5.45
375,745
17.77M
US$ 18.480M
US$ 1.25
-0.01 -0.79
75,548
14.75M
US$ 18.440M
US$ 0.30
0.03 11.40
273,910
61.77M
US$ 18.350M
US$ 1.03
-0.03 -2.83
67,312
17.55M
US$ 18.080M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 3.29
-0.56 -14.55
185,273
5.43M
US$ 17.860M
US$ 0.30
-0.04 -12.18
2.78M
59.12M
US$ 17.740M
US$ 9.15
0.93 11.31
88,355
1.92M
US$ 17.570M
US$ 0.53
0.03 4.95
15,645
32.69M
US$ 17.330M
US$ 2.03
0.03 1.65
126,192
8.47M
US$ 17.220M
US$ 3.40
-0.24 -6.51
25,433
5.04M
US$ 17.140M
US$ 0.23
-0.01 -4.23
1.75M
74.11M
US$ 17.120M
C$ 0.03
0.00 0.00
60,000
541.70M
C$ 16.250M
US$ 0.25
0.01 4.60
924,106
64.53M
US$ 16.130M
US$ 0.41
0.003 0.73
463,603
38.32M
US$ 15.790M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 2.50
1.15 85.19
62.10M
6.15M
US$ 15.380M
US$ 3.22
-0.05 -1.53
37,067
4.75M
US$ 15.300M
US$ 0.49
-0.01 -2.41
280,566
31.06M
US$ 15.060M
US$ 1.44
-0.02 -1.37
14,174
10.17M
US$ 14.640M
US$ 2.16
-0.07 -2.93
12,045
6.66M
US$ 14.350M
C$ 0.11
0.02 15.79
80,315
129.86M
C$ 14.280M
US$ 3.10
-0.12 -3.58
13,137
4.59M
US$ 14.210M
US$ 1.45
0.04 2.84
49,578
9.66M
US$ 14.010M
US$ 2.20
-0.12 -5.17
179,514
6.29M
US$ 13.840M
US$ 0.38
0.0077 2.06
93,375
35.43M
US$ 13.500M
C$ 0.10
0.00 0.00
146,994
140.64M
C$ 13.360M
US$ 0.32
0.01 3.39
75,185
41.49M
US$ 13.280M
US$ 1.14
0.03 2.25
2,552
11.70M
US$ 13.280M
US$ 0.32
-0.02 -5.55
617,987
41.55M
US$ 13.090M
US$ 1.29
-0.03 -1.91
99,236
10.17M
US$ 13.070M
US$ 0.76
0.02 2.15
204,731
16.85M
US$ 12.820M
C$ 0.13
0.00 0.00
7,250
96.40M
C$ 12.530M
US$ 0.41
-0.02 -3.95
256,094
30.17M
US$ 12.460M
US$ 3.87
-0.39 -9.06
152,397
3.21M
US$ 12.410M
US$ 0.32
-0.24 -43.29
338,034
38.27M
US$ 12.130M
US$ 1.13
0.01 0.89
23,584
10.71M
US$ 12.100M
US$ 0.23
-0.01 -5.53
455,045
51.37M
US$ 12.020M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 1.67
-0.04 -2.34
23,656
6.92M
US$ 11.560M
US$ 0.41
-0.03 -7.33
93,791
28.01M
US$ 11.540M
US$ 0.13
0.03 30.00
75,647
88.13M
US$ 11.460M
C$ 0.04
0.00 0.00
0
280.65M
C$ 11.230M
US$ 2.15
0.04 1.90
2,465
5.17M
US$ 11.120M
US$ 1.56
0.02 1.08
3,170
6.99M
US$ 10.870M
US$ 0.28
0.02 7.43
219,641
38.67M
US$ 10.790M
US$ 0.41
0.01 3.25
506,883
25.92M
US$ 10.700M
US$ 2.32
-0.45 -16.25
154,723
4.58M
US$ 10.630M
US$ 0.25
0.01 5.53
780,794
41.27M
US$ 10.480M
C$ 0.03
0.00 0.00
85,752
418.56M
C$ 10.460M
US$ 3.34
-0.12 -3.47
5,694
3.12M
US$ 10.420M
US$ 1.87
0.34 22.22
65,671
5.43M
US$ 10.150M
US$ 1.71
-0.19 -10.21
27,492
5.70M
US$ 9.720M
US$ 0.13
-0.01 -10.02
17.87M
72.48M
US$ 9.570M
US$ 3.13
0.04 1.41
6,882
3.00M
US$ 9.390M
C$ 0.03
0.00 0.00
0
308.61M
C$ 9.260M
C$ 0.07
-0.01 -13.33
536,300
137.51M
C$ 8.940M
US$ 0.91
-0.007 -0.77
205,680
9.44M
US$ 8.570M
US$ 7.55
-0.13 -1.69
12,180
1.12M
US$ 8.460M
US$ 0.33
-0.007 -2.06
106,089
25.15M
US$ 8.370M
US$ 0.36
0.0051 1.46
57,785
23.13M
US$ 8.210M
US$ 0.56
-0.05 -8.30
816,879
14.50M
US$ 8.150M
US$ 2.92
-0.13 -4.25
4,815
2.71M
US$ 7.910M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 0.62
-0.005 -0.81
138,505
12.85M
US$ 7.900M
US$ 0.56
0.03 5.10
965,894
14.09M
US$ 7.830M
US$ 4.74
-0.15 -3.07
6,030
1.63M
US$ 7.730M
US$ 0.50
0.02 3.93
139,772
15.10M
US$ 7.550M
US$ 0.83
-0.04 -4.60
80,571
8.99M
US$ 7.460M
US$ 0.18
-0.01 -7.72
6.15M
41.75M
US$ 7.430M
US$ 1.78
-0.08 -4.30
196,729
4.17M
US$ 7.420M
US$ 0.11
0.0013 1.16
10.38M
65.46M
US$ 7.400M
US$ 0.37
-0.05 -11.67
153,823
19.49M
US$ 7.290M
US$ 1.04
-0.005 -0.48
5,154
6.97M
US$ 7.250M
US$ 0.83
-0.11 -11.73
111,899
8.47M
US$ 7.010M
US$ 2.00
-0.03 -1.48
20,910
3.47M
US$ 6.940M
US$ 0.73
-0.0001 -0.01
471,175
9.39M
US$ 6.840M
US$ 1.18
0.04 3.51
41,120
5.70M
US$ 6.730M
US$ 1.05
0.01 0.97
35,239
6.10M
US$ 6.370M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 0.85
-0.02 -2.18
127,751
6.90M
US$ 5.870M
US$ 0.95
-0.11 -10.38
179,300
6.03M
US$ 5.730M
US$ 2.20
-0.04 -1.79
22,364
2.58M
US$ 5.680M
US$ 3.50
0.00 0.00
0
1.61M
US$ 5.640M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 5.02
0.11 2.24
3,517
1.10M
US$ 5.520M
US$ 7.65
7.30 2.00
175,530
696,249
US$ 5.330M
US$ 0.98
-0.06 -5.77
28,160
5.35M
US$ 5.240M
US$ 2.24
0.05 2.28
3,537
2.23M
US$ 5.000M
US$ 2.15
-0.10 -4.44
62,438
2.30M
US$ 4.940M
US$ 9.74
1.06 12.21
195,393
505,798
US$ 4.930M
US$ 0.41
-0.02 -4.39
33,407
12.01M
US$ 4.860M
US$ 1.90
0.00 0.00
12,571
2.51M
US$ 4.770M
US$ 3.09
-0.03 -0.96
3,371
1.54M
US$ 4.760M
US$ 1.06
-0.03 -2.30
79,729
4.34M
US$ 4.600M
US$ 2.82
-0.07 -2.42
4,940
1.60M
US$ 4.510M
C$ 0.05
0.00 0.00
290,010
90.29M
C$ 4.510M
US$ 1.01
0.04 4.12
413,502
4.43M
US$ 4.470M
US$ 4.86
0.10 2.10
83,671
914,234
US$ 4.440M
US$ 1.60
-0.05 -2.79
10,186
2.76M
US$ 4.430M
US$ 0.66
0.01 1.54
80,395
6.47M
US$ 4.270M
US$ 0.97
0.00 0.00
44,989
4.38M
US$ 4.250M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 1.10
-0.14 -11.29
519,258
3.65M
US$ 4.020M
US$ 3.63
-0.14 -3.71
12,252
1.09M
US$ 3.960M
US$ 0.77
0.08 11.24
491,909
5.09M
US$ 3.890M
US$ 2.92
0.19 6.96
15,708
1.32M
US$ 3.850M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 0.25
-0.10 -28.57
9,961
14.89M
US$ 3.720M
US$ 0.51
0.00 0.00
0
7.24M
US$ 3.710M
US$ 1.23
-0.07 -5.02
48,009
3.01M
US$ 3.700M
C$ 0.03
0.00 0.00
0
121.27M
C$ 3.640M
C$ 0.08
-0.005 -5.88
7,000
44.79M
C$ 3.580M
US$ 0.28
0.0019 0.68
360,877
12.48M
US$ 3.490M
US$ 1.98
-0.06 -2.94
19,288
1.75M
US$ 3.460M
US$ 0.28
-0.02 -6.57
3,801
12.27M
US$ 3.440M
US$ 0.31
-0.01 -3.74
243,404
10.83M
US$ 3.310M
US$ 1.44
-0.05 -3.42
19,754
2.25M
US$ 3.240M
US$ 2.33
-0.07 -3.08
16,950
1.36M
US$ 3.170M
US$ 0.94
-0.06 -5.53
17,505
3.23M
US$ 3.040M
US$ 0.94
-0.05 -4.84
21,803
3.22M
US$ 3.030M
US$ 0.51
-0.02 -4.36
2.73M
5.90M
US$ 2.990M
US$ 0.91
-0.08 -8.16
635,248
3.19M
US$ 2.910M
US$ 3.94
0.19 5.12
29,119
736,431
US$ 2.900M
US$ 0.01
0.00 0.00
0
261.79M
US$ 2.880M
US$ 0.58
-0.02 -2.52
31,829
4.89M
US$ 2.840M
US$ 2.14
-0.17 -7.36
233,373
1.30M
US$ 2.780M
US$ 2.23
-0.16 -6.69
40,446
1.21M
US$ 2.700M
US$ 0.06
-0.02 -24.00
89,231
41.30M
US$ 2.600M
US$ 1.33
-0.08 -5.36
40,367
1.93M
US$ 2.560M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.20
-0.0008 -0.41
678,899
12.59M
US$ 2.460M
US$ 2.85
0.15 5.56
17,341
852,996
US$ 2.430M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 0.52
-0.32 -37.80
2.29M
4.48M
US$ 2.330M
US$ 1.81
-0.07 -3.72
44,895
1.28M
US$ 2.320M
C$ 0.09
0.00 0.00
0
27.30M
C$ 2.320M
US$ 0.32
0.00 0.00
0
6.96M
US$ 2.210M
US$ 2.95
-0.42 -12.35
325,978
724,152
US$ 2.130M
US$ 1.26
-0.05 -3.82
109,362
1.66M
US$ 2.090M
US$ 0.43
0.01 2.63
36,820
4.75M
US$ 2.040M
US$ 0.24
0.01 6.28
2.74M
8.51M
US$ 2.020M
US$ 0.14
0.00 0.00
0
14.37M
US$ 1.950M
US$ 1.66
0.02 1.22
60,155
1.17M
US$ 1.940M
US$ 0.68
-0.02 -2.65
228,192
2.77M
US$ 1.880M
US$ 0.05
-0.05 -50.00
3,943
36.47M
US$ 1.820M
US$ 0.006
0.00 0.00
0
302.90M
US$ 1.820M
US$ 0.04
-0.05 -56.25
22,458
47.10M
US$ 1.650M
US$ 0.79
0.02 1.93
58,476
2.04M
US$ 1.620M
US$ 0.97
0.0045 0.47
143,947
1.60M
US$ 1.540M
US$ 0.54
-0.03 -4.62
1.03M
2.78M
US$ 1.500M
US$ 1.13
0.01 0.89
64,793
1.30M
US$ 1.470M
US$ 0.30
0.00 0.00
0
4.85M
US$ 1.460M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
C$ 0.01
0.00 0.00
6,559
141.96M
C$ 1.420M
US$ 0.09
-0.60 -87.45
5.53M
16.39M
US$ 1.410M
US$ 0.51
0.0092 1.83
213,606
2.51M
US$ 1.290M
US$ 0.002
0.00 0.00
0
635.88M
US$ 1.270M
US$ 0.10
0.00 0.00
0
12.23M
US$ 1.250M
US$ 0.02
-0.12 -84.14
998
54.39M
US$ 1.250M
US$ 0.85
-0.02 -2.29
18,666
1.44M
US$ 1.220M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.86
-0.09 -9.86
1.21M
1.27M
US$ 1.090M
US$ 1.25
-0.72 -36.39
276
863,788
US$ 1.080M
C$ 0.12
0.02 14.29
9,915
8.86M
C$ 1.060M
US$ 0.20
0.00 0.00
0
4.44M
US$ 888K
US$ 0.03
-0.09 -73.55
2,999
26.83M
US$ 832K
US$ 0.03
0.00 0.00
0
29.49M
US$ 826K
US$ 0.25
0.02 7.26
2.73M
3.27M
US$ 821K
US$ 0.18
-0.03 -14.29
2,176
4.31M
US$ 776K
C$ 0.02
0.00 0.00
0
38.74M
C$ 775K
US$ 1.30
-0.01 -0.76
32,257
580,840
US$ 755K
US$ 0.02
-0.0058 -25.44
350
39.74M
US$ 676K
US$ 0.08
-0.02 -19.18
29.83M
8.29M
US$ 622K
US$ 0.33
0.00 0.00
724,133
1.46M
US$ 482K
US$ 0.21
-0.21 -50.00
4,159
2.05M
US$ 431K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.009
-0.01 -56.10
1.29M
34.87M
US$ 314K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.05
0.02 47.40
822.15M
3.93M
US$ 200K
US$ 0.003
-0.0004 -11.76
15
61.76M
US$ 185K
US$ 0.001
0.0003 42.86
100
172.20M
US$ 172K
US$ 0.03
0.00 0.00
0
3.41M
US$ 109K
US$ 0.001
-0.08 -98.72
1,140
100.08M
US$ 100K
US$ 0.009
0.00 0.00
397.90M
4.19M
US$ 38K
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
US$ 0.08
-0.01 -11.11
5,352
-
US$ -
US$ 0.15
0.03 25.00
405,233
-
US$ -
US$ 0.00
0.00 0.00
0
44.57M
US$ -
US$ 0.00
-0.04 -100.00
9,622
54.52M
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 0.00
0.00 0.00
0
30.74M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.70M
US$ -
US$ 0.00
-3.82 -100.00
500
3.14M
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
6.58M
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
-0.69 -100.00
1,000
10.88M
US$ -
US$ 0.00
0.00 0.00
0
42.08M
US$ -
US$ 0.00
0.00 0.00
0
71.42M
US$ -
US$ 0.00
0.00 0.00
0
112.91M
US$ -
US$ 0.00
-0.0002 -100.00
87.89M
5.12B
US$ -
US$ 0.00
-0.0003 -100.00
2,363
514.01M
US$ -
US$ 0.34
-0.02 -5.56
88,040
-
US$ -
US$ 1.45
-0.02 -1.36
156,959
-
US$ -
C$ 1.85
0.00 0.00
0
-
C$ -
US$ 4.71
0.31 7.05
107,652
-
US$ -

Latest Biotechnology Stock News


HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2025.  On May 15, 2025, the Company closed... Read more


CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent claims A hearing on infringement of EP 4 023 755 B1 which will also include EP 3 708 668 B1, the validity of which was confirmed in amended form in March 2025, is scheduled for July 1, 2025, before the Regional Court Düsseldorf, Germany TUBINGEN,... Read more


Omeros Reports First Quarter 2025 Financial Results

Conference Call Today at 4:30 p.m. ET SEATTLE / May 15, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024. At March 31, 2025, we had $52.4 million of cash... Read more


Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

SAN DIEGO / May 15, 2025 / Business Wire / Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can... Read more


Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

PDUFA target action date of January 13, 2026 If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO / May 15, 2025 / Business Wire / Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal... Read more


Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions Findings Presented at the 2025 American Association of Clinical Endocrinology Annual Meeting SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)... Read more


Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025  FA (SGT-212): Dosing of first participant anticipated in the second half of 2025  CPVT (SGT-501): FDA IND on track for submission first half of 2025  Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has... Read more


Crinetics Pharmaceuticals to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients  Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates  SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting... Read more


Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed  Topline Results Announcement from PROSERA Phase 3 Expected in February 2026  To Date, Blinded Baseline Characteristics Align with Intended Study Population  First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025  Cash, cash equivalents and marketable... Read more


Molecular Partners Reports Financial Results and Highlights from Q1 2025

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027 IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programs Data from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol... Read more


Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable... Read more


Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up RP-A601 promoted increased protein expression and desmosomal localization of Plakophilin-2 (PKP2), Desmocollin-2, and Cadherin-2 in all three patients Improvement or stabilization observed in arrhythmia burden, heart function, and quality of life in all patients No further dose escalation planned Investor webinar to be... Read more


Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapy Patients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival WILMINGTON, Del. / May 15, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration... Read more


vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitiated in the Company’s CATT1 Phase 3 trial investigating c... Read more


MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CHICAGO / May 15, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3, 2025, in Chicago, Illinois. The poster... Read more


Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Presenting new data in the most mature readout to date, with 60% more patients and reported median and 2-year overall survival. LEXINGTON, Mass. / May 15, 2025 / Business Wire / Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European... Read more


Avalo Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Updates

Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dy... Read more


HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term  MIAMI, May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical... Read more


Sona Nanotech Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin testing ("BET") on Sona's uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate ("LAL") method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US. Sona Nanotech CEO, David... Read more


Arcutis Biotherapeutics: New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and...

Arcutis convened the Genital Psoriasis Wellness Consortium, a multidisciplinary group of clinicians who are experts in their fields Publication includes 14 consensus statements aimed at improving diagnosis, treatment, outcomes, and shared decision-making Genital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis WESTLAKE VILLAGE, Calif., May 15, 2025 (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq:... Read more


PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and... Read more


Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from... Read more


SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first pediatric AML patient... Read more


GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”)  Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) and over two-thirds enrollment completed for the overall trial Cash runway expected to fund operations through Q3 2025 LA JOLLA, CA, May 15, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI... Read more


IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications LAWRENCEVILLE, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation... Read more


Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area of high unmet need Data demonstrates significant improvement in response rates compared to historical controls, and safety continues to be favourable Multi-centre INSIGHT-003 is evaluating the same immunot... Read more


BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce... Read more


Journal of Clinical Nuclear Medicine Publishes Results of Tiziana Life Sciences’ Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a new study in the Journal of ‘Clinical Nuclear Medicine’ demonstrating that intranasal administration of foralumab significantly dampened... Read more


Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration; IND amendment submission expected in Q2 2025 High dose and low dose... Read more


Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Oppor

Antimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis MIAMI, FL / ACCESS Newswire / May 15, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced the identification of Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections,... Read more


Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich... Read more


Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here. The event will feature key opinion leaders (KOLs) Fred Hayden, MD, FACP (University of Virginia... Read more


Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine... Read more


Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025

REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced poster presentations from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment of hyperphagia associated PWS at the Pediatric Endocrine Society (PES) Meeting 2025, which is... Read more


NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025 Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational results for the first quarter ended March 31, 2025. "We continue to make important progress in the clinical development... Read more


Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)  U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC)  Entered into sales agreement for priority review voucher (PRV) for $155 million  CLEVELAND,... Read more


Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

PONTE VEDRA, Fla. / May 15, 2025 / Business Wire / Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy. Cadrenal completed the technical transfer and manufacturing of its... Read more


MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the... Read more


ADC Therapeutics to Present at Upcoming Investor Conferences

LAUSANNE, Switzerland, May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: May 21, 2025Presentation Time: 10:30-10:55 a.m. ETFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerTo register for the webcast, click here. Jefferies Global... Read more


Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expenses Since Emergency Use Authorization (EUA)... Read more


Voyager Therapeutics Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV... Read more


Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial  RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg  Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development program; 44 patients enrolled and 23 patients dosed as of May 9,... Read more


GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry,... Read more


OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

NEW YORK / May 15, 2025 / Business Wire / OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the launch of OS Animal Health, Inc., a wholly owned subsidiary focused on commercializing OST-HER2 for the treatment of canine osteosarcoma. OST-HER2 market opportunity in canine osteosarcoma exceeds $150 million Recent data in prevention of amputation... Read more


Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function,... Read more


Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation

$3 Million Lead Order from Strategic Investors Supports Bold Transformation VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a strategic financing of approximately $4 million (the “Offering”) consisting of concurrent private... Read more


Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants... Read more


Covalon Technologies Announces Promotion of Kim Crooks to Chief Operating Officer and Appointment to Board of Directors

MISSISSAUGA, Ontario / May 15, 2025 / Business Wire / Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce the promotion of Ms. Kim Crooks to the position of Chief Operating Officer (COO), effective immediately. In addition to her new role, Ms. Crooks has been appointed to Covalon's Board of Directors. Ms. Crooks rejoined Covalon in early 2024 as Senior Vice President – Operations,... Read more


GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Andrew Ritter to its Board of Directors. Mr. Ritter will be replacing current board member Dr. Rajesh Shrotriya, who is resigning from his position. “We... Read more


Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok. These events reflect Anbio’s strategic commitment to... Read more